Research Analysts Offer Predictions for AGIO Q3 Earnings

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Equities researchers at Zacks Research reduced their Q3 2025 earnings per share estimates for shares of Agios Pharmaceuticals in a research note issued on Wednesday, October 23rd. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will earn ($1.80) per share for the quarter, down from their prior forecast of ($1.79). The consensus estimate for Agios Pharmaceuticals’ current full-year earnings is ($4.87) per share. Zacks Research also issued estimates for Agios Pharmaceuticals’ Q4 2025 earnings at ($1.79) EPS, FY2025 earnings at ($6.99) EPS, Q1 2026 earnings at ($1.63) EPS, Q2 2026 earnings at ($1.57) EPS, Q3 2026 earnings at ($1.52) EPS and FY2026 earnings at ($5.95) EPS.

A number of other research analysts have also commented on AGIO. Scotiabank assumed coverage on Agios Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $51.00 price objective on the stock. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Agios Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $52.00.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $45.09 on Friday. The stock’s fifty day moving average price is $44.64 and its two-hundred day moving average price is $41.58. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28. The firm has a market cap of $2.56 billion, a price-to-earnings ratio of -7.13 and a beta of 0.75.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The firm had revenue of $8.60 million during the quarter, compared to analyst estimates of $9.34 million. During the same period in the prior year, the company earned ($1.51) earnings per share. The business’s quarterly revenue was up 28.4% compared to the same quarter last year.

Hedge Funds Weigh In On Agios Pharmaceuticals

Several large investors have recently bought and sold shares of AGIO. Farallon Capital Management LLC raised its position in Agios Pharmaceuticals by 34.1% in the first quarter. Farallon Capital Management LLC now owns 5,590,602 shares of the biopharmaceutical company’s stock valued at $163,469,000 after purchasing an additional 1,423,000 shares during the last quarter. Marshall Wace LLP raised its position in Agios Pharmaceuticals by 307.8% in the second quarter. Marshall Wace LLP now owns 1,133,735 shares of the biopharmaceutical company’s stock valued at $48,887,000 after purchasing an additional 855,739 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Agios Pharmaceuticals by 23.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,012,993 shares of the biopharmaceutical company’s stock valued at $58,861,000 after purchasing an additional 388,381 shares during the last quarter. Frazier Life Sciences Management L.P. raised its position in Agios Pharmaceuticals by 66.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 871,974 shares of the biopharmaceutical company’s stock valued at $37,600,000 after purchasing an additional 348,808 shares during the last quarter. Finally, Candriam S.C.A. bought a new position in shares of Agios Pharmaceuticals during the second quarter worth about $13,922,000.

Insider Buying and Selling

In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian Goff sold 11,091 shares of the company’s stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.